First international proficiency study on human papillomavirus testing in cervical cancer screening.

Background: Although cervical screening using Human Papillomavirus (HPV) testing is globally recommended public health policy, there has been no international proficiency studies specifically targeting HPV testing for cervical screening.

Objective: To obtain the first global overview of the current proficiency of HPV testing services for cervical cancer screening.

Study Design: A coded proficiency panel of 12 samples containing HPV types 16, 18, 31, 33, 45, 52, 58 or 35/39/51/56/59/68 in human DNA in varying amounts as well as control.

Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study.

Background: Proficient Human Papillomavirus (HPV) genotyping services are essential to support HPV and cervical cancer elimination strategies, in particular to support HPV vaccine research.

Objectives: To perform a global HPV genotyping proficiency study, with evaluation in relation to previous proficiency studies.

Study Design: The proficiency panel contained 44 coded samples (40 samples containing one or more purified HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/68a/68b) in human DNA, 1 human DNA control and 3 DNA extraction controls).

The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing.

Background: Accurate and internationally comparable human papillomavirus (HPV) testing services are essential for cervical cancer elimination programs. The WHO HPV Laboratory Network started issuing international HPV testing proficiency panels in 2008.

Objectives: We report the results of the 2019 global proficiency study and evaluate the proficiency over time.